In July 2020, IBBL saw its ISO 17025 (General requirements for the competence of testing and calibration laboratories) accreditation renewed, following a successful audit in June 2020.
Following a “virtual” audit that took place in June 2020, the Luxembourg Office of Accreditation and Surveillance (Office Luxembourgeois d’Accréditation et de Surveillance – OLAS) confirmed the prolongation of the biobank’s ISO 17025 accreditation.
The accreditation specifies the general requirements for the competence of testing and calibration laboratories and enables them to demonstrate that they operate competently and generate valid results, thereby promoting confidence in their work both nationally and internationally. Specifically, IBBL’s accreditation scope covers the following methods developed in-house:
- DNA Quantification by Spectrofluorometry;
- Nucleic Acid Quantification by Spectrophotometry;
- RNA Integrity Measurement;
- 16s rRNA Gene Sequencing.
In addition, the biobank transitioned to the latest version of the norm, i.e. ISO 17025:2017.
“This reaccreditation is an important achievement for our biobank, further confirming our reputation as a quality-driven organisation”, comments Dr Sabine Lehmann, Head of IBBL & Transversal Translational Medicine (TTM) Quality Management. “The dedication and competence of our staff have been a decisive element in the positive outcome of the audit and are indeed IBBL’s greatest asset”, she concludes.
IBBL’s reaccreditation certificate was issued on July 6th 2020 and is valid until May 28th 2023.